ArticleCritical care (London, England)2021
A high blood endocan profile during COVID-19 distinguishes moderate from severe acute respiratory distress syndrome.
Article in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Endocan as a biomarker for acute respiratory distress syndrome: A systematic review and meta-analysis.Health science reports · 2024Review
- Investigation of Serum Endocan Levels in SARS-CoV-2 Patients.International journal of molecular sciences · 2024Article
- Changes in plasma endocan level are related to circulatory but not respiratory failure in critically ill patients with COVID-19.Scientific reports · 2023Observational
- Investigation of Serum Endocan Levels and Age in Critical Inflammatory Conditions.International journal of molecular sciences · 2023Article
- MR-proADM as Prognostic Factor of Outcome in COVID-19 Patients.Biomedicines · 2023Article
- Assessment of plasma endocan for the prediction of mortality in COVID-19 patients undergoing veno-venous ECMO: A pilot study.Medicina intensiva · 2023Article
- SARS-CoV-2 Infection and Candidate Biomarkers.The Eurasian journal of medicine · 2022Article
- Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients.Journal of clinical medicine · 2022Article
- Can Serum Endocan Levels be Used as an Early Prognostic Marker for Endothelial Dysfunction in COVID-19?Angiology · 2022Article
- Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.Biomolecules · 2022Review
- Is endocan correlated to ARDS severity or an epiphenomenon of thrombo-embolic disease in COVID.Critical care (London, England) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.